Ucello Therapeutics, a developer of allogeneic universal chimeric antigen receptor (CAR)-T cell therapies based in Chengdu, has reportedly raised RMB 150 million (USD 21.2 million) in a Series A+ financing round. The funding was led by Juke Investment, with contributions from Guozhong Capital and Penglai Capital, as well as existing investors Matrix Partners China and Co-Win Ventures among others.
Expanding Industrialization and Market Presence
Founded in 2020, Ucello Therapeutics plans to utilize the funds to accelerate the industrialization of its allogeneic universal CAR-T product. The company aims to strengthen its position in the market by focusing on new drug application filings and preparing for product launches. This financing round will significantly bolster Ucello Therapeutics’ efforts to bring innovative CAR-T therapies to patients in need.
Strategic Investment and Growth Prospects
The investment from Juke Investment and other contributors underscores the confidence in Ucello Therapeutics’ approach to CAR-T cell therapy development. With the financial backing, the company is well-positioned to advance its pipeline and contribute to the growing field of immunotherapy. The funding will also support the company’s broader strategic goals, including market expansion and the pursuit of new partnerships and collaborations.-Fineline Info & Tech
